Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

ference in the ALS- Functional Score between the therapies tested was large enough, and comparison to the historical controls was non-futile at the 6-month time point, we were able to finish the trial early after just 60 patients," stated Dr. Gordon. "We originally planned to enroll up to 120 patients, in sequential pools of 60. Our ability to halt the trial early underscores the potential efficacy of AL-08, which can be further evaluated in a Phase III ALS clinical trial."

"We are pleased that AL-08/celecoxib slowed deterioration in ALS- Functional Score compared to the other treatment and believe that results of this trial highlight the potential of this combination treatment for ALS patients," stated Belinda Tsao Nivaggioli, CEO and Chairman of Avicena. "We are eager to proceed with designing our Phase III clinical trial which will attempt to confirm the efficacy of AL-08".

About the Trial

The randomized, double-blind, selection trial targeted enrollment of up to 120 patients in sequential pools of 60 to evaluate the neuroprotective capacity of two drug combinations, AL-08/ minocycline and AL-08/celecoxib. The trial used a group sequential design and a natural history control group for a futility analysis. The primary objective was treatment selection based on which drug combination appeared to slow deterioration in the ALS-Functional Score.

Patients were randomized to receive daily administration of AL- 08/minocycline or AL-08/celecoxib. The trial was stopped early after the first pool of 60 patients when the selection criteria was met by showing a large enough difference in ALS-Functional Score between the two treatment arms.

Results showed that patients treated with AL-08/celcoxib showed a smaller mean functional decline versus AL-08/minocycline. At the end of the trial, the decline in ALS-Functional Score in both treatment arms was compared separately to the mean historical control group at a 0.05 significance level. The mea
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  Heska Corporation (Nasdaq: HSKA ) announces ... Its Third Quarter 2014 Earnings Conference Call on the ... 11:00 a.m. (EDT)Where: , www.heska.com (click on ... page of this website)How:Live over the Internet -- Simply ... Alternatively, you may use the following teleconference access numbers:  ...
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... Metanome, Inc. , a Houston -based ... the genomic sequencing provider for Seres Health,s ( ... SER 109, an Ecobiotic® therapeutic for the treatment of ... Metanome has provided genomic sequencing services in ... genomic characterization has enabled the study of the microbiota ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... FORD, Pa., Oct. 12, 2011 Endo Pharmaceuticals (Nasdaq: ... results on October 27, 2011 and will host a conference ... discuss these results.   David P. Holveck, president ... Ivan Gergel, executive vice president of R&D, Alan Levin, executive ...
... Aircraft Medical ("Aircraft"), the UK medical devices company, today ... Covidien (NYSE: COV ), a leading global ... billion, and 41,000 employees worldwide. Under the ... Aircraft,s proprietary McGRATH ® MAC video laryngoscope in ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... Reinberg HealthDay Reporter FRIDAY, ... common cold sores -- herpes simplex -- might increase the ... In fact, being a carrier of certain antibodies to ... researchers found. "The identification of a treatable cause ... breakthrough," said lead researcher Dr. Hugo Lovheim, an associate professor ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... spot increased risks for certain cancers, one might think that ... But a new study suggests that, at least with colon ... their genes doubled their risk of colon cancer were no ... "It didn,t make any difference, not at all," said ...
(Date:10/22/2014)... 22, 2014 Medical Solutions ... is happy to announce that our co-founder and ... Industry Analysts’ Staffing 100 for 2014. Anderson was ... most influential people in the staffing industry,” in ... the 13th-largest healthcare staffing company in the U.S., ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company,(Nasdaq: ... filed an Abbreviated New,Drug Application (ANDA) for over-the-counter ... a generic version of Monistat(R) 1,Combination Pack. The ... file an ANDA,with a Paragraph IV certification against ...
... CLEARWATER, Fla., April 21 Lincare Holdings,Inc. (Nasdaq: ... respiratory,therapy services delivered to patients in the home, today ... 2008., For the quarter ended March 31, 2008, ... $378.5 million for the first quarter of 2007.,The Company ...
... 21 In honor of their 25th,anniversary, Sierra Tucson ... April 30, 2008, from 8:30 -- 10:00 a.m. at ... S. Doheny Drive, Los,Angeles, CA 90048. Over 200 attendees ... their peers., Among those being recognized for their ...
... People with scalp or neck melanomas die at nearly ... body, including the face or ears, researchers at the University ... analysis of 51,704 melanoma cases in the U.S. confirms that ... Those with scalp or neck melanomas die at a rate ...
... enforcement agencies intensifying focus on hospital-physician ... ... /PRNewswire/ - The Deloitte Forensic Center reports,that complying with ... hospitals. Almost all physicians have ethical, mutually,beneficial relationships with ...
... West Nile Virus and Other Diseases, SACRAMENTO, Calif., ... hand. Coinciding with the launch of mosquito season, the,California ... April 25,2008 West Nile Virus and Mosquito and Vector ... mosquito-borne disease that can result in,debilitating cases of meningitis ...
Cached Medicine News:Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 2Health News:Perrigo Confirms Patent Challenge of Monistat(R) 1 Combination Pack 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2008 Financial Results 5Health News:Most lethal melanomas are on scalp and neck 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 2Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 3Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 4Health News:Video: Antifraud Compliance Getting More Complex for Hospitals 5Health News:State Legislature Declares April 21 to 25, 2008 West Nile Virus and Mosquito and Vector Control Awareness Week 2
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
Medicine Products: